Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...

An Orlando-based 503B pharmaceutical company is now serving clients in Alabama. Olympia Pharmaceuticals, an FDA-registered ...

Kenox Pharmaceuticals Inc., a company dedicated to developing innovative Orally Inhaled and Nasal Drug Products (OINDPs), has ...

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

Allurion Technologies (NYSE: ALUR) shares are moving higher Friday potentially after after the company announced plans to ...

Shares of Allurion Technologies (NYSE: ALUR) skyrocketed by 350% following the company's announcement of its plans to ...

The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.

The Allurion Virtual Care Suite is also available to providers separately from the ... including the clinical study on the combination of the Allurion Program with GLP-1 agonists, (iii) the evolution ...